← All trials
NCT04857372
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2021
- Primary completion
- May 23, 2024
- Completion date
- May 23, 2024
- First posted
- Apr 23, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 156
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NovartisLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.